Chapter 2 Summary and Highlights
- Market Outlook
- Market Summary
Chapter 3 Market Overview
- Kinase Inhibitors
- Types of Kinase Inhibitors
- Tyrosine Kinase Inhibitors
- Regulatory Scenario
- Market Dynamics
- Drivers
- Restraints
- Opportunities
Chapter 4 Market Breakdown by Type and Application
- Market for Tyrosine Kinase Inhibitors, by Type
- Receptor Tyrosine Kinase Inhibitors
- Non-receptor Tyrosine Kinase Inhibitors
- Market for Tyrosine Kinase Inhibitors, by Application
- Lung Cancer
- Chronic Myelogenous Leukemia (CML)
- Others
Chapter 5 Market Breakdown by Region
- Global Market for Tyrosine Kinase Inhibitors, by Region
- North America
- Europe
- Asia-Pacific
- Rest of the World
Chapter 6 ESG Development
- Introduction to ESG
- The Sustainability of Tyrosine Kinase Inhibitor Manufacturers in the Industry
- Pharma End User Sustainability in the Industry
- Case Study
- Publisher's Viewpoint
Chapter 7 Industry Structure
- Ranking of Top Companies
- Pipeline Analysis
- Patent Analysis
- Emerging Trends
Chapter 8 Company Profiles
- Astrazeneca
- Bayer Ag
- Boehringer Ingelheim International Gmbh
- Bristol-Myers Squibb Co.
- Eisai Co. Ltd.
- F. Hoffmann-La Roche Ltd.
- Johnson & Johnson Services Inc.
- Novartis Ag
- Pfizer Inc.
List of Tables
Summary Table: Global Market for Tyrosine Kinase Inhibitors, by Region, Through 2028
Table 1: Characteristics of ATP-competitive and Non-ATP Competitive Inhibitors
Table 2: Types of Receptor Tyrosine Kinase Inhibitors
Table 3: Types of Non-receptor Tyrosine Kinase Inhibitors
Table 4: FDA-approved Kinase Inhibitors, 2001-2021
Table 5: FDA-approved Tyrosine Kinase Inhibitors and Their Drug Targets
Table 6: EMA-approved Kinase Inhibitors, 2001-2020
Table 7: Patent Expiration Dates of Tyrosine Kinase Inhibitors
Table 8: Global Market for Tyrosine Kinase Inhibitors, by Type, Through 2028
Table 9: Global Market for Receptor Tyrosine Kinase Inhibitors, by Region, Through 2028
Table 10: Global Market for Non-receptor Tyrosine Kinase Inhibitors, by Region, Through 2028
Table 11: Approved Tyrosine Kinase Inhibitors and Their Targets and Indications
Table 12: Global Market for Tyrosine Kinase Inhibitors, by Application, Through 2028
Table 13: Global Market for Tyrosine Kinase Inhibitors Used to Treat Lung Cancer, by Region, Through 2028
Table 14: Global Market for Tyrosine Kinase Inhibitors Used to Treat CML, by Region, Through 2028
Table 15: Global Market for Tyrosine Kinase Inhibitors Used in Other Applications, by Region, Through 2028
Table 16: Global Market for Tyrosine Kinase Inhibitors, by Region, Through 2028
Table 17: North American Market for Tyrosine Kinase Inhibitors, by Type, Through 2028
Table 18: North American Market for Tyrosine Kinase Inhibitors, by Application, Through 2028
Table 19: North American Market for Tyrosine Kinase Inhibitors, by Country, Through 2028
Table 20: European Market for Tyrosine Kinase Inhibitors, by Type, Through 2028
Table 21: European Market for Tyrosine Kinase Inhibitors, by Application, Through 2028
Table 22: European Market for Tyrosine Kinase Inhibitors, by Country, Through 2028
Table 23: Asia-Pacific Market for Tyrosine Kinase Inhibitors, by Type, Through 2028
Table 24: Asia-Pacific Market for Tyrosine Kinase Inhibitors, by Application, Through 2028
Table 25: Asia-Pacific Market for Tyrosine Kinase Inhibitors, by Country, Through 2028
Table 26: Rest of the World Market for Tyrosine Kinase Inhibitors, by Type, Through 2028
Table 27: Rest of the World Market for Tyrosine Kinase Inhibitors, by Application, Through 2028
Table 28: Key Focus Areas in ESG Metrics
Table 29: ESG Rankings for Major Pharma Companies Manufacturing TKIs, 2023
Table 30: Revenue from Sales of Selected Tyrosine Kinase Inhibitors, 2020-2022
Table 31: Ongoing Clinical Trials of Various Tyrosine Kinase Inhibitors
Table 32: Patents Filed on Tyrosine Kinase Inhibitors, 2018-2022
Table 33: AstraZeneca: Tyrosine Kinase Inhibitor Drug Product Portfolio
Table 34: Bayer AG: Tyrosine Kinase Inhibitor Drug Product Portfolio
Table 35: Boehringer Ingelheim International GmbH: Tyrosine Kinase Inhibitor Drug Product Portfolio
Table 36: Bristol-Myers Squibb Co.: Tyrosine Kinase Inhibitor Drug Product Portfolio
Table 37: Eisai Co. Ltd.: Tyrosine Kinase Inhibitor Drug Product Portfolio
Table 38: F. Hoffmann-La Roche Ltd.: Tyrosine Kinase Inhibitor Drug Product Portfolio
Table 39: Johnson & Johnson Services Inc.: Tyrosine Kinase Inhibitor Drug Product Portfolio
Table 40: Novartis AG: Tyrosine Kinase Inhibitor Drug Product Portfolio
Table 41: Pfizer Inc.: Tyrosine Kinase Inhibitor Drug Product Portfolio
List of Figures
Summary Figure A: Global Market Shares of Tyrosine Kinase Inhibitors, by Region, 2022
Summary Figure B: Growth Rate of North America, Europe, and Asia-Pacific Markets for Tyrosine Kinase Inhibitors, 2023-2028
Figure 1: Share of Estimated Number of New Cancer Cases Among Women, by Cancer Type, 2020
Figure 2: Share of Estimated Number of New Cancer Cases Among Men, by Cancer Type, 2020
Figure 3: National Cancer Institute Research Funding, 2012-2019
Figure 4: Global Market Shares of Tyrosine Kinase Inhibitors, by Type, 2022
Figure 5: Global Market Shares of Tyrosine Kinase Inhibitors, by Application, 2022
Figure 6: Global Mrket for Tyrosine Kinase Inhibitors, by Region
Figure 7: Global Market Shares of Tyrosine Kinase Inhibitors, by Region, 2022
Figure 8: Global Market Shares of Tyrosine Kinase Inhibitors by Region, 2028
Figure 9: How a Strong ESG Proposition Benefits Businesses
Figure 10: The 10 Business Sustainability Trends Identified for 2022
Figure 11: ESG Adoption Level Across All Industries, 2021 and 2022
Figure 12: Key Sustainable Practices Being Implemented in Research Laboratories
Figure 13: ESG Commitments of Pfizer
Figure 14: Company Shares of the Market for Tyrosine Kinase Inhibitors, 2022
Figure 15: Distribution Share of Clinical Trial Phases of Various Tyrosine Kinase Inhibitors
Figure 16: Number of Patents Filed, Granted and Published, 2018-March 2023
Figure 17: Timeline of Kinase Inhibitors, Since 2001
